SECsense Logo

Xeris Biopharma Holdings, Inc. 8-K Report: Key Updates for Investors - Feb 2025

$XERS
Form 8-K
Filed on: 2025-02-24
Source
Xeris Biopharma Holdings, Inc. 8-K Report: Key Updates for Investors - Feb 2025

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Entity Information:
  • Company Name: Xeris Biopharma Holdings, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK (Central Index Key): 0001867096
  • SEC File Number: 001-40880
  • EIN (Employer Identification Number): 87-1082097
  • Headquarters Address: 1375 West Fulton Street, Suite 1300, Chicago, IL 60607
  • Contact Number: 844-445-5704
  1. Filing Information:
  • Filing Type: 8-K (a form used to report major events that shareholders should know about)
  • Filing Date: February 24, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Ticker Symbol: XERS
  • Exchange: NASDAQ
  1. Reporting Period:
  • Report Date: February 24, 2025 (the start and end date for this filing are the same, indicating it may cover a specific event or announcement on that date).
  1. XBRL Information:
  • The document is structured in XBRL (eXtensible Business Reporting Language), which is used for the electronic communication of business and financial data.

Overall, this report indicates a significant event or announcement related to Xeris Biopharma Holdings, Inc. on February 24, 2025, as reported through an 8-K filing. The details provided are essential for investors and stakeholders to understand the company's status and any developments that may impact financial performance.